Ascelia Pharma: Wrap up from interview Deputy CEO Julie W. Brogren
Ascelia Pharma yesterday participated at an event with HCA Capital following the release of its Q1 report last week. Although up more than 175 percent this year following the securing of non-diluting financing, successful completion of its pivotal SPARKLE study, and the recent release of very strong headline data from the study, Ascelia Pharma’s shares has actually been sliding more than 25 percent the last month. This probably reflect investors awaiting more details regarding the upcoming process of submitting an NDA (New Drug Application) for Orviglance to FDA and the plans for the commercialization process, so at yesterday’s event with HCA Capital, Deputy CEO and Chief Commercial Officer Julie Waras Brogren explained the company’s plans for the coming quarters on these matters sending up the shares almost 10 percent. Among other things Julie Waras Brogren confirmed ambitions that an Orphan Drug Designation and serving an unmet need will help Orviglance achieve a large share of the addressable market of approximately USD 400 millions annually in US. Ascelia Pharma could choose a standard or priority review from FDA, it is not unlikely that Orviglance will begin to be sold through partnerships already late 2025 or in the beginning of 2026.
To see the full event, use this link: Ascelia Pharma Q1 event
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. /Claus thestrup 08:50 AM 22-05-2024.
Ascelia Pharma
Ascelia Pharma er et svensk biotek selskab med fokus på behandling af sjældne kræftsygedomme. De udvikler og markedsfører nye lægemidler, hvor der er behov for bedre behandlingsmuligheder eller hvor der ikke findes muligheder for behandling i dag, og de har en klar go-to-market strategi. Ascelia Pharma har to kandidater i pipelinen, Orviglance og Oncoral. Orviglance er et nyt kontrastmiddel til MR-scanning, og udviklet til at forbedre opdagelsen og visualiseringen af fokale leverlæsioner(Inklusiv levermetastaser – og primære tumorer) hos patienter med nedsat lever funktion. Oncoral er en tablet med en potent anti-tumor effekt, der indtages på daglig basis. Oncoral har vist god effekt ved kræftformer der er svære at behandle, og en bedre virkning/bivirkningsprofil for patienten sammenlignet med intravenøs behandlinger med høj dose udført på et hospital. Ascelia Pharma er noteret på Nasdaq Small Cap Stockholm med ticker ACE.
Read more on company page